Last reviewed · How we verify
AZD0486
AZD0486 is a selective inhibitor of the mechanistic target of rapamycin complex 1 (mTORC1) that suppresses protein synthesis and cell proliferation in cancer cells.
AZD0486 is a selective inhibitor of the mechanistic target of rapamycin complex 1 (mTORC1) that suppresses protein synthesis and cell proliferation in cancer cells. Used for Advanced or metastatic solid tumors with mTOR pathway activation.
At a glance
| Generic name | AZD0486 |
|---|---|
| Also known as | TNB-486, Surovatamig |
| Sponsor | AstraZeneca |
| Drug class | mTORC1 inhibitor |
| Target | mTORC1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
AZD0486 binds to and inhibits mTORC1, a key signaling complex that regulates cell growth, metabolism, and survival. By blocking mTORC1 activity, the drug reduces protein synthesis and induces cell cycle arrest, leading to reduced proliferation of cancer cells. This mechanism is particularly relevant in tumors with dysregulated mTOR pathway signaling.
Approved indications
- Advanced or metastatic solid tumors with mTOR pathway activation
Common side effects
- Stomatitis
- Rash
- Diarrhea
- Fatigue
- Hyperglycemia
Key clinical trials
- AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL (PHASE3)
- A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients (PHASE3)
- A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma (PHASE1)
- Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL (PHASE2)
- A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies (PHASE1, PHASE2)
- AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD0486 CI brief — competitive landscape report
- AZD0486 updates RSS · CI watch RSS
- AstraZeneca portfolio CI